MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
Stock Stats
News
Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $117.00 to $125.00. They now have a "buy" rating on the stock.
Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases [Yahoo! Finance]
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: VANGUARD GROUP INC
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: BJERKHOLT ERIC
Form 4 Mirum Pharmaceuticals, For: Mar 16 Filed by: Ramasastry Saira
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Quan Joanne
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Radovich Peter
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.